Evidence map›Paper›PMID 40056335›Full record

ArticleInternational journal of clinical pharmacy2025

Defining histamine H2 receptor antagonist response in critically ill patients with heart failure: a machine learning cluster analysis.

Li-Juan Yang, Fang Yu, Yu Chen, Xin Zhang, Sun-Jun Yin, Ping Wang, Meng-Han Jiang, Hai-Ying Yang, Jia-De Zhu, Ran Xu and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Li-Juan Yang *Department of Clinical Pharmacy, 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China.
Fang Yu *Department of Clinical Pharmacy, 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China.
Yu Chen *Department of Cardiology, 920th Hospital of Joint Logistics Support Force, PLA, Kunming, 650032, China.
Xin Zhang *Department of Respiratory, 920th Hospital of Joint Logistics Support Force, Kunming, 650032, China.
Sun-Jun YinDepartment of Clinical Pharmacy, 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China.
Ping WangDepartment of Clinical Pharmacy, 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China.
Meng-Han JiangDepartment of Clinical Pharmacy, 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China.
Hai-Ying YangDepartment of Clinical Pharmacy, 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China.
Jia-De ZhuDepartment of Clinical Pharmacy, 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China.
Ran XuDepartment of Clinical Pharmacy, 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China.
Wen-Ke CaiDepartment of Cardiothoracic Surgery, 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China.
Gong-Hao HeDepartment of Clinical Pharmacy, 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China. gonghow@hotmail.com.ORCID http://orcid.org/0000-0002-1274-3130

Funding

the Applied Basic Research Program Yunnan Province of China No. 202101AY070001-300the Applied Basic Research Program Yunnan Province of China No. 202401AY070001-367the National Science Foundation of China No. 81960664the Scientific Research Fund of Yunnan Provincial Education Department No. 2024Y254the Young and Middle-aged Academic and Technical Leaders Reserve Talent Project of Yunnan Province No. 202405AC350037
6 · The paper itself

Abstract

backgroundRecent studies showed histamine H2 receptor antagonists (H2RAs) exposure was associated with reduced mortality in heart failure (HF) patients. However, specific HF patients who are sensitive to H2RAs exposure or not are yet to be further defined.

aimThis study aimed to identify HF patient characteristics that may benefit from H2RAs exposure.

methodNeural network-based variational autoencoders and Gaussian Mixture Model (GMM) clustering methods were employed to classify the critically ill patients with HF exposed to H2RAs based on Medical Information Mart for Intensive Care III and IV databases. Binary logistic and multivariable Cox regression analysis based on propensity score matching (PSM) were employed to estimate the association between H2RAs exposure of each cluster and all-cause mortality of included patients.

resultsA total of 9,585 H2RAs users among 23,855 included HF patients were identified into four clusters according to GMM clustering: cluster 1 (combined with acute kidney failure, septic shock, and pneumonia), cluster 2 (combined with atrial fibrillation), cluster 3 (combined with coronary artery disease (CAD) and/or had higher urine output), and cluster 4 (co-administered with calcium-antagonists). The cluster 3 patients were significantly associated with reduced all-cause mortality compared with non-H2RAs users after PSM, which were further validated in 14,280 HF patients from the large multi-center electronic intensive care unit Collaborative Research Database (eICU-CRD).

conclusionHistamine H2 receptor antagonist exposure was more sensitive in HF patients who were combined with CAD. Furthermore, male HF patients or those with higher urine output were also sensitive to H2RAs exposure.

Indexed as

Critical IllnessHeart FailureHistamine H2 AntagonistsMachine LearningAgedCluster AnalysisFemaleHumansMaleMiddle AgedHistamine H2 AntagonistsCluster analysisHeart failureHistamine H2 antagonistsMachine learningMedical information mart for intensive careMortality

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.